UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

_________________________________

Date of Report

June 1723, 2020

(Date of earliest event reported)

ERBA Diagnostics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	1-14798	11-3500746
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

14100 NW 57^th Court Miami Lakes, Florida		33014
(Address of principal executive offices)		(Zip Code)

(305) 324-2300

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 51.0201 ~~Departure~~Entry ofinto ~~Directors~~a orMaterial ~~Certain~~Definitive ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Agreement.

~~(e) On~~Item ~~June 17, 2020, the Compensation Committee of the Board of Directors of ERBA Diagnostics, Inc~~2.01 ~~(the~~Completion ~~“Company”), as well as the independent directors on the Board~~ of ~~Directors~~Acquisition ofor ~~the~~Disposition ~~Company, approved a one-time payment to David Barka, the Company’s Interim Chief Executive Officer, in the amount~~ of ~~one hundred fifty thousand dollars ($150,000), payable June 18, 2020, for the services he has provided as the Company’s Interim Chief Executive Officer and approved a one-time retainer for Mr~~Assets. ~~Barka in the amount of one hundred fifty thousand dollars ($150,000), payable July 2, 2020, for his continued services as the Company’s Interim Chief Executive Officer.~~

AsOn ~~previously~~June ~~reported~~23, ~~since~~2020, ~~Mr.~~ERBA ~~Barka’s~~Diagnostics, ~~appointment~~Inc. as (the ~~Company’s~~“Corporation”), ~~Interim~~entered ~~Chief~~into, ~~Executive~~and ~~Officer~~consummated inthe ~~July~~transactions ~~2017~~contemplated by, ~~the~~a ~~Company~~Deed ~~has~~of ~~not~~Sale ~~paid~~(the ~~Mr.~~“Deed ~~Barka~~of ~~any~~Sale”) ~~compensation~~with ~~for~~Inovabio ~~his~~S.r.l., ~~services~~Redix asConsulting ~~the~~Limited Liability Company’s ~~Interim~~and ~~Chief~~Kolodziejczyk ~~Executive~~Waldemar ~~Officer~~(collectively, ~~because~~the “Buyers”, inand ~~addition~~each, a “Buyer”), pursuant to ~~serving~~which asthe Buyers purchased from the ~~Company’s~~Corporation ~~Interim~~all ~~Chief~~of ~~Executive~~the ~~Officer~~issued and outstanding shares of capital stock in Delta Biologicals, MrS.r.l ~~Barka~~(“Delta”), ~~has~~the ~~also~~Corporation’s ~~served,~~wholly ~~and~~owned ~~continues~~subsidiary tolocated ~~serve~~in Italy (the “Acquisition”), asfor ~~President~~the aggregate net purchase price of ~~Calbiotech~~50,000 ~~Inc~~Euros (the “Purchase Price”). At the closing of the Acquisition, ~~President~~each of ~~Calbiotech~~the ~~Veterinary~~Buyers ~~Diagnostics,~~issued ~~and~~a ~~President~~promissory note in favor of ~~Microplate~~the ~~Dispensers~~Corporation, ~~Inc.~~which ~~d/b/a~~promissory ~~Moduline~~notes ~~Systems,~~collectively ~~all~~have an aggregate principal amount of ~~which~~the Purchase Price, are ~~direct~~due orand ~~indirect~~payable ~~subsidiaries~~on June 22, 2021, and were registered with the government of ~~Erba~~the ~~Diagnostics~~Italian ~~Mannheim~~Republic. ~~GmbH~~The Acquisition, the ~~majority~~Deed ~~stockholder~~of Sale and each of the ~~Company~~promissory ~~(“Erba~~notes ~~Mannheim”)~~are governed by the laws of the Italian Republic.

Mr. Barka continues to serve as the Company’s Interim Chief Executive Officer and oversees the business and operations of the Company and its wholly owned subsidiaries. As the Company’s Interim Chief Executive Officer, Mr. Barka’s continuing role is also expected to include, among other things, assisting the Company in its efforts to find and train a permanent successor to the role of the Company’s Chief Executive Officer. Mr. Barka’s employment with the Company continues to be at-will and may be terminated by the Company or by Mr. Barka at any time for any reason or for no reason.SIGNATURES

AsPursuant ~~previously~~to ~~reported, Erba Mannheim beneficially owns, directly or indirectly, approximately 83.3% of~~ the ~~outstanding~~requirements ~~shares~~ of the ~~Company’s~~Securities ~~common~~Exchange ~~stock.~~Act Asof ~~also previously reported~~1934, the ~~Company~~registrant ~~and~~has ~~its~~duly ~~wholly~~caused ~~owned~~this ~~subsidiaries,~~report onto ~~the~~be ~~one~~signed ~~hand,~~on ~~and Erba Mannheim and~~ its ~~affiliates,~~behalf onby the ~~other~~undersigned ~~hand,~~hereunto ~~have~~duly ~~engaged in and are currently engaged in a number of commercial transactions~~authorized.

SIGNATURES

	ERBA DIAGNOSTICS, INC.



Dated: July 6, 2020	By:	/s/ David Barka
		David Barka,
		Interim Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ERBA DIAGNOSTICS, INC.
Dated: June 17, 2020	By:	/s/ David Barka
		David Barka,
		Interim Chief Executive Officer

Filing Compare · ERBA Diagnostics, Inc.